US3935245A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radioactively labeled steroid derivatives
Assignee: Bayer Pharma AG
•
Filing: 1974-06-04
•
Granted: 1976-01-27
•
Expires: 1994-06-04
Abstract
Abstract Steroids bearing the substituent --X-NR 1 R 2 wherein --NR 1 R 2 is a tritium of carbon-14 labeled amino or amino-acid group and --X-- is --R 3 --, --OCOR 3 --, =N--O--R 3 -- or --NHCOR 3 -- wherein R 3 is --(CH 2 ) n CO-- in which n is 0-4, are useful as diagnostic agents.
Inventors
- 👤 Otto Engelfried
- 👤 Bob Nieuweboer
- 👤 Karl Petzoldt
- 👤 Ulrich Kerb
- 👤 Klaus Lubke
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 18:19
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0493; C; C07; C07J; C07J1/00; C07J1/0003; C07J1/0011; C07J1/0018; C07J1/0022; C07J1/0025; C07J1/0051; C07J1/0059; C07J1/0066; C07J1/007; C07J1/0081; C07J1/0088; C07J1/0096; C07J13/00; C07J13/005; C07J41/00; C07J41/0005; C07J43/00; C07J43/003; C07J53/00; C07J53/002; C07J53/004; C07J53/005; C07J7/00; C07J7/0005; C07J7/001; C07J7/0015; C07J7/002; C07J7/0025; C07J7/003; C07J71/00; C07J71/0005; C07J71/001; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N33/743; A61K2121/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
60 words
a radioactive labeled steroid bearing the radical --X--N--R 1 R 2 wherein --NR 1 R 2 is a tritium- or carbon-14 labeled amino or aminoacid radical and X is R 3 , --O--CO--R 3 , =N--O--R 3 or --NH--CO--R 3 wherein R 3 is --(CH 2 ) n --CO-- in which n is an integer from 0 to 4, inclusive.
Claim 2
Dependent Claim
60 words
a radioactive labeled steroid bearing the radical --X--N--R 1 R 2 wherein --NR 1 R 2 is a tritium- or carbon-14 labeled amino or aminoacid radical and X is R 3 , --O--CO--R 3 , =N--O--R 3 or --NH--CO--R 3 wherein R 3 is --(CH 2 ) n --CO-- in which n is an integer from 0 to 4, inclusive.
Claim 3
Dependent Claim
10 words
The compound of claim 1, N-[(3,17β-dihydroxy-1,3,5(10)-estratriene-6β-yl)-acetyl]-L-tyrosine-[3,5- 3 H 2 ].
Claim 4
Dependent Claim
10 words
The compound of claim 1, N-[(17α-ethinyl-3,17β-dihydroxy-1,3,5(10)-estratriene-6β-yl)-acetyl]-L-tyrosine-[3,5- 3 H 2 ].
Claim 5
Dependent Claim
10 words
The compound of claim 1, N-[17α-ethinyl-17β-hydroxy-3-oxo-4-estren-11α-yloxysuccinyl]-L-tyrosine-[3,5- 3 H 2 ].
Claim 6
Dependent Claim
10 words
The compound of claim 1 N-[17α-acetoxy-6-chloro-1α,2α-methylene-3,20-dioxo-4,6-pregnadien-11α-yloxysuccinyl]-L-tyrosine-[3,5- 3 H 2 ].
Claim 7
Dependent Claim
10 words
The compound of claim 1, N-[(3,17β-dihydroxy-1,3,5(10)-estratrien-6β-yl)-aminosuccinyl]-L-phenylalanine[2,3- 3 H 2 ].
Claim 8
Dependent Claim
10 words
The compound of claim 1, N-[1-methyl-3-oxo-5α-androst-1-en-17β-yloxysuccinyl]-L-phenylalanine-[2,3- 3 H 2 ].
Claim 9
Dependent Claim
10 words
The compound of claim 1, N-[(3-hydroxy-17-oxo-1,3,5(10)-estratrien-6β-yl)-acetyl]-histamine-[2,5- 3 H 2 ].
Claim 10
Dependent Claim
10 words
The compound of claim 1, N-[17α-ethinyl-17β-hydroxy-18-methyl-3-oxo-4-estren-6β-yloxysuccinyl]-histamine-[2,5- 3 H 2 ].
Claim 11
Dependent Claim
8 words
The compound of claim 1, N-[(3,16α,17β-trihydroxy-1,3,5(10)-estratrien-6β-yl)-acetyl]-proline-[μ- 14 C].
Claim 12
Dependent Claim
8 words
The compound of claim 1, N-[3,20-dioxo-4-pregnen-6α-yloxysuccinyl]-proline-[μ- 14 C].
Claim 13
Dependent Claim
8 words
The compound of claim 1, N-[3β-heptanoyloxy-17-oxo-5-androsten-7α-yloxysuccinyl]-proline-[μ- 14 C].
Claim 14
Dependent Claim
10 words
The compound of claim 1, N-[(∫α-ethinyl-3,17β-dihydroxy-1,3,5(10)-estratrien-6-ylidene)-amino-oxyacetyl]-dopamine-[2,3- 3 H 2 ].
Claim 15
Dependent Claim
10 words
The compound of claim 1, N-[6α-fluoro-11β-hydroxy-16α-methyl-3,20-dioxo-1,4-pregnadien-21-yloxysuccinyl]-dopamine-[2,3- 3 H 2 ].
Claim 16
Dependent Claim
10 words
The compound of claim 1, N-[(3,16α,17β-trihydroxy-1,3,5(10)-estratrien-6β-yl)-aminosuccinyl]-L-leucine-[4,5- 3 H 2 ].
Claim 17
Dependent Claim
10 words
The compound of claim 1, N-[17α-ethinyl-17β-hydroxy-3-oxo-4-androsten-7α-yloxysuccinyl]-L-leucine-[3,5- 3 H 2 ].
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-01-26 | 1979-07-28 | 1980-01-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-01-26 | 1983-07-28 | 1984-01-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-01-26 | 1987-07-28 | 1988-01-27 | $7700.00 | Window Closed / Lapsed |